Comparing the current results to its competitors, Kamada Ltd reported Revenue increase in the 4 quarter 2025 by 14.54 % year on year. The revenue growth was below Kamada Ltd 's competitors' average revenue growth of 18.39 %, achieved in the same quarter.
Kamada Ltd 's Comment on Competition and Industry Peers
The Proprietary Products segment operates in a competitive plasma industry market, facing competition from established biopharmaceutical companies including CSL Behring, Takeda, Grifols S.A. (which acquired Talecris Biotherapeutics, Inc. in 2011), Octapharma, Kedrion (excluding KEDRAB), Biotest AG, and ADMA Biologics Inc. Competition involves licenses, expertise, third-party strategic partnerships, and market share for specific products. The company depends significantly on third-party distributors, and any disruptions in these relationships could negatively impact operations and profitability.
May 1, 2024
Kamada Ltd., a frontrunning global biopharmaceutical firm with a robust portfolio of approved products designed to mitigate the effects of rare and serious conditions, has announced that it will publicize its financial results for the first quarter ending March 31, 2024. As per their statement, the company will release results before the U.S. financial markets begin their trading session on Wednesday, May 8, 2024. With its headquarter in Rehovot, Israel, and another base in Hoboken, New Jersey, Kamada Ltd. has established itself as a leading player in the specialized plasma-derived field. Over the years, their commitment to tackling challenging diseases and conditions has led to numerous breakthroughs, provi...
Kamada Ltd., a renowned global biopharmaceutical company specializing in rare and serious conditions, has recently signed a game-changing agreement with Kedrion, a key player in the field of specialty plasma-derived products. The collaboration aims to enhance the distribution of KEDRAB, Kamada s innovative pharmaceutical product, in the United States. With this partnership, Kamada anticipates generating approximately $180 million in revenues over the first four years of the agreement, marking a significant milestone for the company. The binding memorandum of understanding between Kamada and Kedrion outlines an amendment and extension to their existing U.S. distribution agreement for KEDRAB. As ...
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
Sources:
Kamada Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kamada Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
